Adnan Jaigirdar, MD, FACS, provides an overview of the U.S. Food and Drug Administration (FDA) expanded access program (compassionate use) for investigative therapies for mesothelioma patients. Dr. Jaigirdar is a surgical oncologist in the thoracic oncology group at the FDA.
For more information about the expanded access (compassionate use) program, please visit https://www.fda.gov/about-fda/oncology-center-excellence/project-facilitate.
Watch MesoTV
This MesoTV interview was made possible by the support of sponsors who have stepped up during this difficult time to ensure that we can continue serving the mesothelioma community. Please take note of them at the beginning of the video: Novocure; Belluck & Fox, LLP; University of Pittsburgh Medical Center (UPMC); The Gori Law Firm; Vogelzang Law; and Merrill Lynch.
Get notified when our next video is published by clicking the red “Subscribe” button below.
MesoTV is the Mesothelioma Applied Research Foundation’s recorded video series covering pertinent conversations impacting the mesothelioma community. You can learn more at curemeso.org/mesotv.
